Hadasit Bio-Holdings Ltd
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HSITF research report →
Companywww.hbl.co.il
Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It primarily focuses on the therapeutic areas, including oncology, regenerative medicine, and inflammatory disease. The company offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases.
- CEO
- Yuval Adar
- IPO
- 2010
- Employees
- 2
- HQ
- Jerusalem, IL
Price Chart
Valuation
- Market Cap
- $1.33M
- P/E
- -2.65
- P/S
- 0.00
- P/B
- 5.89
- EV/EBITDA
- -8.67
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -152.91%
- ROIC
- -110.63%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-3,461,000 · 88.14%
- EPS
- $-0.31 · 88.21%
- Op Income
- $-1,702,000
- FCF YoY
- 14.86%
Performance & Tape
- 52W High
- $0.13
- 52W Low
- $0.12
- 50D MA
- $0.12
- 200D MA
- $0.12
- Beta
- 0.49
- Avg Volume
- 77
Get TickerSpark's AI analysis on HSITF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HSITF Coverage
We haven't published any research on HSITF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HSITF Report →